Cell Therapy Market - Global Forecast 2026-2032

The Cell Therapy Market is projected to reach USD 7.21 Billion in 2026. It is expected to continue growing at a CAGR of 12.59%, reaching USD 14.73 Billion by 2032.

Cell therapy is moving from a breakthrough modality into a core pillar of advanced healthcare, spanning CAR T-cell therapy, tumor-infiltrating lymphocyte therapy, hematopoietic stem cell transplantation, mesenchymal stromal cell applications, induced pluripotent stem cell platforms, and emerging allogeneic cell therapy programs. Since the first U.S. FDA approval of a CAR T-cell therapy in 2017, regulators have authorized multiple cellular medicines for hematologic malignancies, and the 2024 U.S. approval of the first TIL therapy for advanced melanoma further validated the clinical and therapeutic relevance of engineered and expanded living medicines.

The cell therapy market is being shaped by strong demand in oncology, rising investment in autoimmune and inflammatory disease programs, advances in cell therapy manufacturing, and the need for scalable, quality-controlled supply chains. For industry leaders, the most defensible opportunities are forming where clinical efficacy, durable patient response, manufacturing reliability, reimbursement readiness, and real-world evidence generation converge.

Transformative Shifts in the Cell Therapy Landscape

The cell therapy landscape is shifting from individualized, hospital-centered treatment pathways toward more industrialized platforms that can support broader patient access. Autologous CAR T-cell therapy remains a benchmark for clinical value in blood cancers, but long vein-to-vein timelines, complex logistics, and high production costs are accelerating development of allogeneic, in vivo, and automated manufacturing models.

Scientific progress is also widening the addressable disease base. Cell therapies are advancing beyond hematologic malignancies into solid tumors, autoimmune diseases, rare genetic disorders, regenerative medicine, and transplant-related indications. At the same time, regulators are emphasizing potency assays, comparability, long-term follow-up, and post-market safety surveillance, making evidence quality a central competitive differentiator.

Cumulative Impact of Artificial Intelligence on Cell Therapy

Artificial intelligence is becoming a cumulative force across the cell therapy value chain by improving target discovery, donor and patient stratification, process development, quality analytics, and clinical trial design. AI-enabled image analysis, multi-omics modeling, and machine learning applied to manufacturing data can help identify potency markers, predict batch variability, and support faster root-cause analysis when deviations occur.

The impact is especially important for cell therapy manufacturing, where living products are sensitive to starting material quality, culture conditions, and logistics. AI does not replace regulatory-grade validation, but it can strengthen process control, reduce failed batches, and support adaptive trial enrollment when integrated with compliant data governance, explainable models, cybersecurity controls, and human oversight.

Key Regional Insights for Cell Therapy

North America remains one of the most mature regions for cell therapy, led by the United States through FDA-approved CAR T-cell therapies, a deep biotechnology financing ecosystem, strong academic medical centers, and established specialty treatment networks. Canada is also advancing through hospital-based cell therapy programs, public research initiatives, and regenerative medicine collaborations, although manufacturing scale, payer coordination, and geographic access remain key priorities.

Europe benefits from the European Medicines Agency’s advanced therapy medicinal product framework and strong translational research clusters across Germany, France, Italy, Spain, and the United Kingdom. The European Union’s centralized regulatory pathway supports cross-border authorization, while country-level health technology assessment, hospital exemption practices, national pricing systems, and reimbursement processes continue to shape launch sequencing and patient access.

Asia-Pacific is expanding as China, Japan, South Korea, India, Australia, and ASEAN markets invest in regenerative medicine, oncology innovation, clinical trial capacity, and domestic manufacturing capabilities. China has built a large clinical development base for CAR T-cell therapy, Japan operates a regenerative medicine regulatory framework designed to support conditional and time-limited access, and South Korea and Australia are strengthening advanced therapy infrastructure through biomanufacturing, translational research, and internationally credible clinical trial systems.

Latin America, the Middle East, and Africa are at earlier but increasingly strategic stages of adoption. Brazil and Mexico are regional anchors for clinical research, transplant capabilities, and specialty oncology care in Latin America. GCC countries are investing in medical hubs, genomics, precision medicine infrastructure, and specialized hospitals, while African markets are gradually building capacity through oncology centers, hematopoietic stem cell transplant programs, public health partnerships, and international collaborations focused on equitable access.

Key Group Insights Across Global Cell Therapy Markets

The European Union and G7 economies are central to cell therapy commercialization because they combine advanced regulatory systems, high healthcare spending, robust intellectual property protection, established pharmacovigilance practices, and mature clinical trial networks. These markets often set global expectations for quality, comparability, long-term safety follow-up, reimbursement evidence, and health economic value demonstration for advanced therapy medicinal products.

BRICS countries are increasingly important to cell therapy development due to large patient populations, rising biomanufacturing capacity, expanding oncology infrastructure, and government support for biotechnology self-reliance. China and India are particularly influential within BRICS, with China leading in cell therapy clinical activity and India expanding cost-efficient bioprocessing, hospital networks, domestic innovation, and access-oriented treatment models.

ASEAN offers a diverse growth corridor where Singapore acts as a biomedical hub and Thailand, Malaysia, Indonesia, Vietnam, and the Philippines continue building capacity in specialty care, clinical research, and regenerative medicine services. GCC markets are investing in high-acuity medical infrastructure, genomics-led healthcare, and medical tourism capabilities, while NATO members overlap significantly with advanced North American and European research ecosystems that support resilient supply chains, clinical collaboration, quality standards, and regulatory alignment.

Key Country Insights in Cell Therapy

The United States leads the global cell therapy market through FDA approvals, academic medical centers, clinical trial activity, specialized treatment networks, and advanced manufacturing capacity. Canada complements this ecosystem with strong public research institutions, cell therapy networks, and hospital-based programs, while Mexico is gaining relevance through specialty care, clinical capabilities, and manufacturing-adjacent opportunities in North America. Brazil is Latin America’s most important cell therapy hub due to its research hospitals, transplant expertise, public health system experience, and expanding oncology infrastructure.

In Europe, the United Kingdom, Germany, France, Italy, and Spain are major centers for advanced therapy research, clinical adoption, regulatory engagement, and reimbursement evaluation. Germany and France provide strong biomanufacturing and hospital networks, the United Kingdom remains influential through innovation pathways, academic excellence, and early-access mechanisms, while Italy and Spain contribute significant transplant, oncology, and hospital-based advanced therapy expertise. Russia maintains scientific capabilities in cell-based research and transplant medicine but faces greater international collaboration, procurement, and supply chain constraints.

In Asia-Pacific, China has become a major center for CAR T-cell therapy development and clinical trials, supported by large patient access, hospital networks, and domestic innovation policies, while India is expanding affordable biotechnology platforms, stem cell research governance, and hospital-based advanced care. Japan’s regenerative medicine framework and established pharmaceutical sector support translation, South Korea is investing in biomanufacturing, cell therapy startups, and regulatory modernization, and Australia provides a strong clinical trial environment, translational research networks, and high regulatory credibility.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize manufacturability as early as clinical design. Programs with clear potency assays, scalable closed-system manufacturing, robust chain-of-identity and chain-of-custody controls, validated cryopreservation strategies, and standardized release testing are better positioned for regulatory review, commercialization, and reliable patient delivery.

Organizations should also build reimbursement evidence from the start by linking clinical endpoints to durability, quality of life, hospital utilization, safety management, and total cost of care. Partnerships with academic centers, contract manufacturers, data platforms, logistics specialists, and payer stakeholders can accelerate development while reducing execution risk in a market where scientific success must be matched by operational excellence.

Research Methodology

This executive summary is developed using a structured secondary research approach aligned with established standards for market intelligence. Inputs include regulatory agency disclosures, clinical trial registries, peer-reviewed literature, public health authority updates, patent and product approval information, reimbursement policy documents, and validated industry sources covering cell therapy, CAR T-cell therapy, stem cell therapy, regenerative medicine, and advanced therapy medicinal products.

The analysis emphasizes triangulation across scientific, regulatory, commercial, manufacturing, and regional indicators. Market interpretations are derived from observable evidence such as therapy approvals, clinical development activity, manufacturing investments, reimbursement pathways, treatment infrastructure, safety requirements, and regional policy frameworks rather than unsupported claims.

Conclusion

Cell therapy is entering a decisive phase in which clinical validation, manufacturing scale, AI-enabled process intelligence, and reimbursement evidence will determine market leadership. The sector’s strongest momentum remains in oncology, but autoimmune disease, regenerative medicine, solid tumor research, and allogeneic platforms are widening the long-term opportunity for advanced cellular medicines.

Organizations that combine scientific differentiation with operational discipline will be best positioned to capture value. As global regions build capacity and regulators refine expectations, the next phase of the cell therapy market will reward stakeholders that can deliver safe, effective, accessible, quality-controlled, and economically sustainable living medicines.

Additional Product Information:

Purchase of this report includes 1 year online access with quarterly updates.
This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Cell Therapy Market, by Type

7.1. Introduction
7.2. Non-stem Cells
7.2.1. CAR-T Cells
7.2.2. Dendritic Cells
7.2.3. NK Cells
7.3. Stem Cells
7.3.1. Embryonic Stem Cells
7.3.2. Hematopoietic Stem Cell
7.3.3. Mesenchymal Stem Cell

8. Cell Therapy Market, by Therapy Type

8.1. Introduction
8.2. Allogenic
8.3. Autologous

9. Cell Therapy Market, by Mode of Administration

9.1. Introduction
9.2. Intramuscular
9.3. Intratumoral
9.4. Intravenous

10. Cell Therapy Market, by Application

10.1. Introduction
10.2. Autoimmune Disorders
10.2.1. Multiple Sclerosis
10.2.2. Rheumatoid Arthritis
10.3. Cancer Treatment
10.3.1. Hematologic Malignancies
10.3.2. Solid Tumors
10.4. Infectious Diseases
10.4.1. Bacterial Infections
10.4.2. Viral Infections
10.5. Regenerative Medicine

11. Cell Therapy Market, by End User

11.1. Introduction
11.2. Academic & Research Institutes
11.3. Clinics
11.4. Commercial Laboratories
11.5. Hospitals

12. Cell Therapy Market, by Region

12.1. Asia-Pacific
12.2. Europe
12.3. North America
12.4. Latin America
12.5. Africa
12.6. Middle East

13. Cell Therapy Market, by Group

13.1. NATO
13.2. G7
13.3. European Union
13.4. BRICS
13.5. ASEAN
13.6. GCC

14. Cell Therapy Market, by Country

14.1. United States
14.2. China
14.3. Germany
14.4. Japan
14.5. India
14.6. United Kingdom
14.7. France
14.8. Canada
14.9. Italy
14.10. Australia
14.11. South Korea
14.12. Brazil
14.13. Mexico
14.14. Russia
14.15. Spain

15. Competitive Landscape

15.1. Market Share Analysis, 2025
15.2. FPNV Positioning Matrix, 2025
15.3. Market Concentration Analysis, 2025
15.3.1. Concentration Ratio (CR)
15.3.2. Herfindahl Hirschman Index (HHI)
15.4. Recent Developments & Impact Analysis, 2025
15.5. Product Portfolio Analysis, 2025
15.6. Benchmarking Analysis, 2025

16. Company Profiles

16.1. Allogene Therapeutics, Inc.
16.2. Anterogen Co., Ltd.
16.3. Astellas Pharma Inc.
16.4. Athersys, Inc.
16.5. BioNTech SE
16.6. Bristol-Myers Squibb Company
16.7. Castle Creek Biosciences, Inc.
16.8. Catalent, Inc.
16.9. FUJIFILM Holdings Corporation
16.10. Gilead Sciences, Inc.
16.11. JCR Pharmaceuticals Co., Ltd.
16.12. Kolon TissueGene, Inc.
16.13. Lonza Group Ltd.
16.14. Lovance Biotherapeutics, Inc.
16.15. Medipost Co., Ltd.
16.16. Mesoblast Ltd.
16.17. Novartis AG
16.18. Pfizer Inc.
16.19. Sartorius AG
16.20. Stemedica Cell Technologies, Inc.
16.21. Stempeutics Research Pvt. Ltd.
16.22. Takeda Pharmaceutical Company Limited
16.23. TegoScience
16.24. Thermo Fisher Scientific, Inc.
16.25. Vericel Corporation

List of Figures

FIGURE 1. GLOBAL CELL THERAPY MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL CELL THERAPY MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL CELL THERAPY MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL CELL THERAPY MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL CELL THERAPY MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL CELL THERAPY MARKET SIZE, BY TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL CELL THERAPY MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025 VS 2032 (%)
FIGURE 9. GLOBAL CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 11. GLOBAL CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL CELL THERAPY MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 13. GLOBAL CELL THERAPY MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL CELL THERAPY MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 15. GLOBAL CELL THERAPY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL CELL THERAPY MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL CELL THERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL CELL THERAPY MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 19. GLOBAL CELL THERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL CELL THERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 21. GLOBAL CELL THERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 23. GLOBAL CELL THERAPY MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

List of Tables

TABLE 1. GLOBAL CELL THERAPY MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL CELL THERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL CELL THERAPY MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL NON-STEM CELLS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL NON-STEM CELLS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL NON-STEM CELLS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL CAR-T CELLS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL CAR-T CELLS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL CAR-T CELLS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL DENDRITIC CELLS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL DENDRITIC CELLS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL DENDRITIC CELLS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL NK CELLS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL NK CELLS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL NK CELLS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL STEM CELLS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL STEM CELLS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL STEM CELLS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL EMBRYONIC STEM CELLS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL EMBRYONIC STEM CELLS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL EMBRYONIC STEM CELLS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL HEMATOPOIETIC STEM CELL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL HEMATOPOIETIC STEM CELL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL HEMATOPOIETIC STEM CELL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL MESENCHYMAL STEM CELL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL MESENCHYMAL STEM CELL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL MESENCHYMAL STEM CELL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL ALLOGENIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL ALLOGENIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL ALLOGENIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL AUTOLOGOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL AUTOLOGOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL AUTOLOGOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL INTRATUMORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL INTRATUMORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL INTRATUMORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL CELL THERAPY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL AUTOIMMUNE DISORDERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL AUTOIMMUNE DISORDERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL AUTOIMMUNE DISORDERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL CANCER TREATMENT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL CANCER TREATMENT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL CANCER TREATMENT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL HEMATOLOGIC MALIGNANCIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL HEMATOLOGIC MALIGNANCIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL HEMATOLOGIC MALIGNANCIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL SOLID TUMORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL SOLID TUMORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL SOLID TUMORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL BACTERIAL INFECTIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL BACTERIAL INFECTIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL BACTERIAL INFECTIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL VIRAL INFECTIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL VIRAL INFECTIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL VIRAL INFECTIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL CELL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL COMMERCIAL LABORATORIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL COMMERCIAL LABORATORIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL COMMERCIAL LABORATORIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL CELL THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 90. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 91. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 92. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2017-2032 (USD MILLION)
TABLE 93. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY STEM CELLS, 2017-2032 (USD MILLION)
TABLE 94. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 95. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 96. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 97. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2017-2032 (USD MILLION)
TABLE 98. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2017-2032 (USD MILLION)
TABLE 99. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 100. ASIA-PACIFIC CELL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 101. EUROPE CELL THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 102. EUROPE CELL THERAPY MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 103. EUROPE CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2017-2032 (USD MILLION)
TABLE 104. EUROPE CELL THERAPY MARKET SIZE, BY STEM CELLS, 2017-2032 (USD MILLION)
TABLE 105. EUROPE CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 106. EUROPE CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 107. EUROPE CELL THERAPY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 108. EUROPE CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2017-2032 (USD MILLION)
TABLE 109. EUROPE CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2017-2032 (USD MILLION)
TABLE 110. EUROPE CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 111. EUROPE CELL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 112. NORTH AMERICA CELL THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 113. NORTH AMERICA CELL THERAPY MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 114. NORTH AMERICA CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2017-2032 (USD MILLION)
TABLE 115. NORTH AMERICA CELL THERAPY MARKET SIZE, BY STEM CELLS, 2017-2032 (USD MILLION)
TABLE 116. NORTH AMERICA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 117. NORTH AMERICA CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 118. NORTH AMERICA CELL THERAPY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 119. NORTH AMERICA CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2017-2032 (USD MILLION)
TABLE 120. NORTH AMERICA CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2017-2032 (USD MILLION)
TABLE 121. NORTH AMERICA CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 122. NORTH AMERICA CELL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 123. LATIN AMERICA CELL THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 124. LATIN AMERICA CELL THERAPY MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 125. LATIN AMERICA CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2017-2032 (USD MILLION)
TABLE 126. LATIN AMERICA CELL THERAPY MARKET SIZE, BY STEM CELLS, 2017-2032 (USD MILLION)
TABLE 127. LATIN AMERICA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 128. LATIN AMERICA CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 129. LATIN AMERICA CELL THERAPY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 130. LATIN AMERICA CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2017-2032 (USD MILLION)
TABLE 131. LATIN AMERICA CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2017-2032 (USD MILLION)
TABLE 132. LATIN AMERICA CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 133. LATIN AMERICA CELL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 134. AFRICA CELL THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 135. AFRICA CELL THERAPY MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 136. AFRICA CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2017-2032 (USD MILLION)
TABLE 137. AFRICA CELL THERAPY MARKET SIZE, BY STEM CELLS, 2017-2032 (USD MILLION)
TABLE 138. AFRICA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 139. AFRICA CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 140. AFRICA CELL THERAPY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 141. AFRICA CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2017-2032 (USD MILLION)
TABLE 142. AFRICA CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2017-2032 (USD MILLION)
TABLE 143. AFRICA CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 144. AFRICA CELL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 145. MIDDLE EAST CELL THERAPY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 146. MIDDLE EAST CELL THERAPY MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 147. MIDDLE EAST CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2017-2032 (USD MILLION)
TABLE 148. MIDDLE EAST CELL THERAPY MARKET SIZE, BY STEM CELLS, 2017-2032 (USD MILLION)
TABLE 149. MIDDLE EAST CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 150. MIDDLE EAST CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 151. MIDDLE EAST CELL THERAPY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 152. MIDDLE EAST CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2017-2032 (USD MILLION)
TABLE 153. MIDDLE EAST CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2017-2032 (USD MILLION)
TABLE 154. MIDDLE EAST CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 155. MIDDLE EAST CELL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 156. GLOBAL CELL THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 157. NATO CELL THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 158. NATO CELL THERAPY MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 159. NATO CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2017-2032 (USD MILLION)
TABLE 160. NATO CELL THERAPY MARKET SIZE, BY STEM CELLS, 2017-2032 (USD MILLION)
TABLE 161. NATO CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 162. NATO CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 163. NATO CELL THERAPY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 164. NATO CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2017-2032 (USD MILLION)
TABLE 165. NATO CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2017-2032 (USD MILLION)
TABLE 166. NATO CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 167. NATO CELL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 168. G7 CELL THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 169. G7 CELL THERAPY MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 170. G7 CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2017-2032 (USD MILLION)
TABLE 171. G7 CELL THERAPY MARKET SIZE, BY STEM CELLS, 2017-2032 (USD MILLION)
TABLE 172. G7 CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 173. G7 CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 174. G7 CELL THERAPY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 175. G7 CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2017-2032 (USD MILLION)
TABLE 176. G7 CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2017-2032 (USD MILLION)
TABLE 177. G7 CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 178. G7 CELL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 179. EUROPEAN UNION CELL THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 180. EUROPEAN UNION CELL THERAPY MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 181. EUROPEAN UNION CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2017-2032 (USD MILLION)
TABLE 182. EUROPEAN UNION CELL THERAPY MARKET SIZE, BY STEM CELLS, 2017-2032 (USD MILLION)
TABLE 183. EUROPEAN UNION CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 184. EUROPEAN UNION CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 185. EUROPEAN UNION CELL THERAPY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 186. EUROPEAN UNION CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2017-2032 (USD MILLION)
TABLE 187. EUROPEAN UNION CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2017-2032 (USD MILLION)
TABLE 188. EUROPEAN UNION CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 189. EUROPEAN UNION CELL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 190. BRICS CELL THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 191. BRICS CELL THERAPY MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 192. BRICS CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2017-2032 (USD MILLION)
TABLE 193. BRICS CELL THERAPY MARKET SIZE, BY STEM CELLS, 2017-2032 (USD MILLION)
TABLE 194. BRICS CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 195. BRICS CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 196. BRICS CELL THERAPY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 197. BRICS CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2017-2032 (USD MILLION)
TABLE 198. BRICS CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2017-2032 (USD MILLION)
TABLE 199. BRICS CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 200. BRICS CELL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 201. ASEAN CELL THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 202. ASEAN CELL THERAPY MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 203. ASEAN CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2017-2032 (USD MILLION)
TABLE 204. ASEAN CELL THERAPY MARKET SIZE, BY STEM CELLS, 2017-2032 (USD MILLION)
TABLE 205. ASEAN CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 206. ASEAN CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 207. ASEAN CELL THERAPY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 208. ASEAN CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2017-2032 (USD MILLION)
TABLE 209. ASEAN CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2017-2032 (USD MILLION)
TABLE 210. ASEAN CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 211. ASEAN CELL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 212. GCC CELL THERAPY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 213. GCC CELL THERAPY MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 214. GCC CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2017-2032 (USD MILLION)
TABLE 215. GCC CELL THERAPY MARKET SIZE, BY STEM CELLS, 2017-2032 (USD MILLION)
TABLE 216. GCC CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 217. GCC CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 218. GCC CELL THERAPY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 219. GCC CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2017-2032 (USD MILLION)
TABLE 220. GCC CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2017-2032 (USD MILLION)
TABLE 221. GCC CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 222. GCC CELL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 223. GLOBAL CELL THERAPY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 224. UNITED STATES CELL THERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 225. UNITED STATES CELL THERAPY MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 226. UNITED STATES CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2017-2032 (USD MILLION)
TABLE 227. UNITED STATES CELL THERAPY MARKET SIZE, BY STEM CELLS, 2017-2032 (USD MILLION)
TABLE 228. UNITED STATES CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 229. UNITED STATES CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 230. UNITED STATES CELL THERAPY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 231. UNITED STATES CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2017-2032 (USD MILLION)
TABLE 232. UNITED STATES CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2017-2032 (USD MILLION)
TABLE 233. UNITED STATES CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 234. UNITED STATES CELL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 235. CHINA CELL THERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 236. CHINA CELL THERAPY MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 237. CHINA CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2017-2032 (USD MILLION)
TABLE 238. CHINA CELL THERAPY MARKET SIZE, BY STEM CELLS, 2017-2032 (USD MILLION)
TABLE 239. CHINA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 240. CHINA CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 241. CHINA CELL THERAPY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 242. CHINA CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2017-2032 (USD MILLION)
TABLE 243. CHINA CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2017-2032 (USD MILLION)
TABLE 244. CHINA CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 245. CHINA CELL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 246. GERMANY CELL THERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 247. GERMANY CELL THERAPY MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 248. GERMANY CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2017-2032 (USD MILLION)
TABLE 249. GERMANY CELL THERAPY MARKET SIZE, BY STEM CELLS, 2017-2032 (USD MILLION)
TABLE 250. GERMANY CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 251. GERMANY CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 252. GERMANY CELL THERAPY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 253. GERMANY CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2017-2032 (USD MILLION)
TABLE 254. GERMANY CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2017-2032 (USD MILLION)
TABLE 255. GERMANY CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 256. GERMANY CELL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 257. JAPAN CELL THERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 258. JAPAN CELL THERAPY MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 259. JAPAN CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2017-2032 (USD MILLION)
TABLE 260. JAPAN CELL THERAPY MARKET SIZE, BY STEM CELLS, 2017-2032 (USD MILLION)
TABLE 261. JAPAN CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 262. JAPAN CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 263. JAPAN CELL THERAPY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 264. JAPAN CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2017-2032 (USD MILLION)
TABLE 265. JAPAN CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2017-2032 (USD MILLION)
TABLE 266. JAPAN CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 267. JAPAN CELL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 268. INDIA CELL THERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 269. INDIA CELL THERAPY MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 270. INDIA CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2017-2032 (USD MILLION)
TABLE 271. INDIA CELL THERAPY MARKET SIZE, BY STEM CELLS, 2017-2032 (USD MILLION)
TABLE 272. INDIA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 273. INDIA CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 274. INDIA CELL THERAPY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 275. INDIA CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2017-2032 (USD MILLION)
TABLE 276. INDIA CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2017-2032 (USD MILLION)
TABLE 277. INDIA CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 278. INDIA CELL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 279. UNITED KINGDOM CELL THERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 280. UNITED KINGDOM CELL THERAPY MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 281. UNITED KINGDOM CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2017-2032 (USD MILLION)
TABLE 282. UNITED KINGDOM CELL THERAPY MARKET SIZE, BY STEM CELLS, 2017-2032 (USD MILLION)
TABLE 283. UNITED KINGDOM CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 284. UNITED KINGDOM CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 285. UNITED KINGDOM CELL THERAPY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 286. UNITED KINGDOM CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2017-2032 (USD MILLION)
TABLE 287. UNITED KINGDOM CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2017-2032 (USD MILLION)
TABLE 288. UNITED KINGDOM CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 289. UNITED KINGDOM CELL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 290. FRANCE CELL THERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 291. FRANCE CELL THERAPY MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 292. FRANCE CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2017-2032 (USD MILLION)
TABLE 293. FRANCE CELL THERAPY MARKET SIZE, BY STEM CELLS, 2017-2032 (USD MILLION)
TABLE 294. FRANCE CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 295. FRANCE CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 296. FRANCE CELL THERAPY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 297. FRANCE CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2017-2032 (USD MILLION)
TABLE 298. FRANCE CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2017-2032 (USD MILLION)
TABLE 299. FRANCE CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 300. FRANCE CELL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 301. CANADA CELL THERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 302. CANADA CELL THERAPY MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 303. CANADA CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2017-2032 (USD MILLION)
TABLE 304. CANADA CELL THERAPY MARKET SIZE, BY STEM CELLS, 2017-2032 (USD MILLION)
TABLE 305. CANADA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 306. CANADA CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 307. CANADA CELL THERAPY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 308. CANADA CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2017-2032 (USD MILLION)
TABLE 309. CANADA CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2017-2032 (USD MILLION)
TABLE 310. CANADA CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 311. CANADA CELL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 312. ITALY CELL THERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 313. ITALY CELL THERAPY MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 314. ITALY CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2017-2032 (USD MILLION)
TABLE 315. ITALY CELL THERAPY MARKET SIZE, BY STEM CELLS, 2017-2032 (USD MILLION)
TABLE 316. ITALY CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 317. ITALY CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 318. ITALY CELL THERAPY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 319. ITALY CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2017-2032 (USD MILLION)
TABLE 320. ITALY CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2017-2032 (USD MILLION)
TABLE 321. ITALY CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 322. ITALY CELL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 323. AUSTRALIA CELL THERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 324. AUSTRALIA CELL THERAPY MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 325. AUSTRALIA CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2017-2032 (USD MILLION)
TABLE 326. AUSTRALIA CELL THERAPY MARKET SIZE, BY STEM CELLS, 2017-2032 (USD MILLION)
TABLE 327. AUSTRALIA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 328. AUSTRALIA CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 329. AUSTRALIA CELL THERAPY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 330. AUSTRALIA CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2017-2032 (USD MILLION)
TABLE 331. AUSTRALIA CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2017-2032 (USD MILLION)
TABLE 332. AUSTRALIA CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 333. AUSTRALIA CELL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 334. SOUTH KOREA CELL THERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 335. SOUTH KOREA CELL THERAPY MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 336. SOUTH KOREA CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2017-2032 (USD MILLION)
TABLE 337. SOUTH KOREA CELL THERAPY MARKET SIZE, BY STEM CELLS, 2017-2032 (USD MILLION)
TABLE 338. SOUTH KOREA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 339. SOUTH KOREA CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 340. SOUTH KOREA CELL THERAPY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 341. SOUTH KOREA CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2017-2032 (USD MILLION)
TABLE 342. SOUTH KOREA CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2017-2032 (USD MILLION)
TABLE 343. SOUTH KOREA CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 344. SOUTH KOREA CELL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 345. BRAZIL CELL THERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 346. BRAZIL CELL THERAPY MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 347. BRAZIL CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2017-2032 (USD MILLION)
TABLE 348. BRAZIL CELL THERAPY MARKET SIZE, BY STEM CELLS, 2017-2032 (USD MILLION)
TABLE 349. BRAZIL CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 350. BRAZIL CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 351. BRAZIL CELL THERAPY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 352. BRAZIL CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2017-2032 (USD MILLION)
TABLE 353. BRAZIL CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2017-2032 (USD MILLION)
TABLE 354. BRAZIL CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 355. BRAZIL CELL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 356. MEXICO CELL THERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 357. MEXICO CELL THERAPY MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 358. MEXICO CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2017-2032 (USD MILLION)
TABLE 359. MEXICO CELL THERAPY MARKET SIZE, BY STEM CELLS, 2017-2032 (USD MILLION)
TABLE 360. MEXICO CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 361. MEXICO CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 362. MEXICO CELL THERAPY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 363. MEXICO CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2017-2032 (USD MILLION)
TABLE 364. MEXICO CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2017-2032 (USD MILLION)
TABLE 365. MEXICO CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 366. MEXICO CELL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 367. RUSSIA CELL THERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 368. RUSSIA CELL THERAPY MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 369. RUSSIA CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2017-2032 (USD MILLION)
TABLE 370. RUSSIA CELL THERAPY MARKET SIZE, BY STEM CELLS, 2017-2032 (USD MILLION)
TABLE 371. RUSSIA CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 372. RUSSIA CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 373. RUSSIA CELL THERAPY MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 374. RUSSIA CELL THERAPY MARKET SIZE, BY AUTOIMMUNE DISORDERS, 2017-2032 (USD MILLION)
TABLE 375. RUSSIA CELL THERAPY MARKET SIZE, BY CANCER TREATMENT, 2017-2032 (USD MILLION)
TABLE 376. RUSSIA CELL THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, 2017-2032 (USD MILLION)
TABLE 377. RUSSIA CELL THERAPY MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 378. SPAIN CELL THERAPY MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 379. SPAIN CELL THERAPY MARKET SIZE, BY TYPE, 2017-2032 (USD MILLION)
TABLE 380. SPAIN CELL THERAPY MARKET SIZE, BY NON-STEM CELLS, 2017-2032 (USD MILLION)
TABLE 381. SPAIN CELL THERAPY MARKET SIZE, BY STEM CELLS, 2017-2032 (USD MILLION)
TABLE 382. SPAIN CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2017-2032 (USD MILLION)
TABLE 383. SPAIN CELL THERAPY MARKET SIZE, BY MODE OF ADMINISTRATION, 2017-2032 (USD MILLION)

Companies Mentioned

Allogene Therapeutics, Inc.
Anterogen Co., Ltd.
Astellas Pharma Inc.
Athersys, Inc.
BioNTech SE
Bristol-Myers Squibb Company
Castle Creek Biosciences, Inc.
Catalent, Inc.
FUJIFILM Holdings Corporation
Gilead Sciences, Inc.
JCR Pharmaceuticals Co., Ltd.
Kolon TissueGene, Inc.
Lonza Group Ltd.
Lovance Biotherapeutics, Inc.
Medipost Co., Ltd.
Mesoblast Ltd.
Novartis AG
Pfizer Inc.
Sartorius AG
Stemedica Cell Technologies, Inc.
Stempeutics Research Pvt. Ltd.
Takeda Pharmaceutical Company Limited
TegoScience
Thermo Fisher Scientific, Inc.
Vericel Corporation

Table Information

Report Attribute	Details
No. of Pages	187
Published	August 2026
Forecast Period	2026 - 2032
Estimated Market Value ( USD ) in 2026	$ 7.21 Billion
Forecasted Market Value ( USD ) by 2032	$ 14.73 Billion
Compound Annual Growth Rate	12.5%
Regions Covered	Global
No. of Companies Mentioned	26

License	Format	Properties	Price
1 - 5 USER LICENSE PDF, Excel and Online Access		This is a 1-5 user license, allowing up to five users have access to the product.	€3184EUR$3,545USD£2,720GBP €3538EUR$3,939USD£3,022GBP
ENTERPRISE LICENSE PDF, Excel and Online Access		This is an enterprise license, allowing all employees within your organization access to the product.	€4817EUR$5,363USD£4,115GBP €5352EUR$5,959USD£4,572GBP

Transformative Shifts in the Cell Therapy Landscape

Cumulative Impact of Artificial Intelligence on Cell Therapy

Key Regional Insights for Cell Therapy

Key Group Insights Across Global Cell Therapy Markets

Key Country Insights in Cell Therapy

Actionable Recommendations for Industry Leaders

Research Methodology

Conclusion

Table of Contents

Companies Mentioned

Table Information

Related Topics

Related Reports

Allogeneic Cell Therapy Market - Global Forecast 2026-2032

Cell Therapy Technologies Market - Global Forecast 2026-2032

Allogeneic Cell Therapy - Global Strategic Business Report

Automated and Closed Cell Therapy Processing Systems - Global Strategic Business Report

Cell and Gene Therapy CRO Market: Industry Trends and Global Forecasts, Till 2035 - Distribution by Type of Cell Therapy, Type of Genetic Modification, Stage of Development, Therapeutic Area, End-Users and Key Geographical Regions